Dr. Taylor on Molecular Testing Recommendations in Ovarian Cancer

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Sarah E. Taylor, MD, assistant professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens Hospital, University of Pittsburgh Medical Center, discusses molecular testing recommendations in ovarian cancer.

Germline testing should be considered for patients who harbor a genetic predisposition to ovarian cancer as their risk of developing cancer is higher than that of the general population, says Taylor. For example, patients with Lynch syndrome have a 40% to 60% risk of developing endometrial cancer.

All patients with a family history of ovarian cancer should undergo molecular testing as up to 20% will develop ovarian cancer, explains Taylor. Moreover, these patients may have a genetic predisposition to other cancer types.

Somatic testing has seen little development in ovarian cancer, says Taylor. Investigating the molecular biology of ovarian cancer tumors in a controlled laboratory setting may provide a more comprehensive understanding of which patients should undergo somatic testing.